The retromer complex is a highly conserved multi-protein assembly that mediates the retrograde transport of transmembrane proteins from endosomes back to the trans-Golgi network (TGN) or the plasma membrane. In the central nervous system, retromer dysfunction has emerged as a convergent pathogenic mechanism across multiple neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, ALS, and FTD. [1]
The retromer plays a critical role in regulating the trafficking of APP, BACE1, sortilin, SorLA/SORL1, and neurotransmitter receptors — all proteins whose mislocalization contributes to neurodegeneration. [2]
Reduced levels of retromer components, particularly VPS35 and VPS26, are found in the hippocampus and entorhinal cortex of AD patients, while the VPS35 D620N mutation causes autosomal dominant late-onset Parkinson's disease — making the retromer both a disease biomarker and a therapeutic target. [3]
The mammalian retromer core consists of a heterotrimer of vacuolar protein sorting (VPS) proteins:
| Subunit | Size | Function |
|---|---|---|
| VPS35 | 92 kDa | Central scaffold; directly binds cargo sorting receptors (SorLA, sortilin, CI-MPR) and recruits VPS26/VPS29 |
| VPS26 (A or B) | 38 kDa | Binds the N-terminal domain of VPS35; recognizes cargo via aromatic-hydrophobic sorting motifs |
| VPS29 | 21 kDa | Binds the C-terminal domain of VPS35; serves as a regulatory platform for retromer-associated proteins |
VPS35 forms an elongated alpha-helical solenoid that bridges VPS26 (at its N-terminus) and VPS29 (at its C-terminus). Mammalian VPS26 has two paralogues — VPS26A and VPS26B — which form distinct retromer complexes with partially overlapping but non-identical cargo specificity.
The cargo-recognition trimer works in concert with:
The retromer retrieves transmembrane cargo from the limiting membrane of maturing endosomes before they fuse with lysosomes. Key neuronal cargoes include:
The retromer also mediates direct recycling from endosomes to the plasma membrane, particularly important for:
The retromer regulates autophagy through trafficking of ATG9A, the only multi-spanning transmembrane protein in the core autophagy machinery. Retromer dysfunction mislocalizes ATG9A, impairing autophagosome formation and compromising clearance of protein aggregates — directly linking retromer deficiency to the protein aggregation seen in neurodegeneration.
Postmortem studies consistently demonstrate reduced levels of VPS35 and VPS26 in the hippocampus and entorhinal cortex of AD patients. This reduction occurs early in disease — detectable at Braak stage III-IV — suggesting that retromer dysfunction precedes widespread tau pathology and neuronal loss. [5]
Retromer dysfunction prolongs the co-residence of APP and BACE1 in acidic endosomal compartments — the primary site of amyloidogenic APP cleavage. When retromer fails to retrieve APP, it remains in endosomes where BACE1 cleaves it to produce amyloid-beta, particularly the more aggregation-prone Aβ42. [6]
SORL1 (encoding SorLA) is a confirmed AD risk gene identified through GWAS. SorLA acts as a "gatekeeper" that shunts APP away from endosomal BACE1 cleavage. Retromer-mediated recycling of SorLA is essential for maintaining this protective function — reduced retromer directly impairs SorLA recycling, creating a vicious cycle of increasing amyloid-beta production. [7] [8] [9]
SORL1 variants are associated with increased AD risk, and the interaction between SORL1 and retromer dysfunction creates a compounded vulnerability. [10]
One of the earliest neuropathological features in AD — detectable decades before symptom onset in Down syndrome patients — is endosomal enlargement in neurons. Retromer dysfunction is a primary driver of this phenotype, as impaired cargo retrieval causes endosomal swelling and disrupted intracellular trafficking.
Retromer stabilization in AD models reduces tau phosphorylation independently of amyloid precursor protein processing, suggesting that retromer dysfunction may contribute to tau pathology through distinct pathways. [11]
In 2011, the VPS35 D620N missense mutation was identified as a cause of autosomal dominant late-onset Parkinson's disease (PARK17) — making VPS35 the first endosomal trafficking gene directly linked to PD. [12] [13]
The D620N mutation impairs retromer function through multiple mechanisms:
A 2024 comprehensive review highlighted that therapeutic targeting of the retromer for PD remains challenging because VPS35 lacks enzymatic activity and functions as a structural scaffold, but pharmacological stabilizers offer a promising alternative. [19] [20]
Retromer stabilization with the compound 2a (a bis-guanylhydrazone) rescued endosomal sorting, attenuated locomotion impairment, and increased motor neuron survival in ALS mouse models, demonstrating retromer dysfunction as a tractable target in ALS. [21]
Retromer dysfunction impairs sorting of progranulin (the product of the GRN gene, a major FTD risk gene), potentially contributing to the lysosomal dysfunction seen in GRN-FTD. [22]
The most promising therapeutic approach is pharmacological chaperone-mediated retromer stabilization — small molecules that bind the VPS35-VPS29 interface to increase retromer complex stability and function:
| Compound | Class | Mechanism | Status |
|---|---|---|---|
| R55 | Thiophene thiourea | Binds VPS35-VPS29 interface; increases retromer levels; reduces APP-BACE1 co-localization | Preclinical — reduces amyloid-beta, restores LTP, normalizes synaptic gene expression in AD mice [23] |
| Compound 2a | Bis-guanylhydrazone | Binds VPS35-VPS29; stabilizes retromer; bioavailable | Preclinical — neuroprotective in ALS mouse model [24] |
| RT-011 | — | Retromer stabilizer; increases VPS35 protein levels | Preclinical |
A 2025 study demonstrated that R55 treatment in an AD mouse model rescued synaptic dysfunction, restored endosomal trafficking, reduced amyloid-beta pathology, and normalized the expression of key synaptic genes (Gria1, Grip1, semaphorin/plexin pathway), providing strong preclinical evidence for retromer stabilization as a disease-modifying strategy. [23:1] [25]
The pharmacological chaperone approach was first validated in 2014 with small molecule retromer stabilizers that reduced amyloidogenic APP processing in cell and mouse models. [26] Subsequent studies extended these findings to human stem cell models of AD. [11:1]
AAV-mediated overexpression of VPS35 has been explored as a gene therapy strategy for PD. In VPS35+/- mice, VPS35 restoration prevents dopaminergic neurodegeneration and normalizes alpha-synuclein levels.
A 2024 review discusses the progress in developing retromer-targeting therapeutics, highlighting the challenges of targeting a non-enzymatic scaffold protein and the promise of pharmacological stabilization approaches. [19:1] The field has advanced from proof-of-concept in cellular models to demonstrated efficacy in multiple animal models of AD, PD, and ALS.
McGough IJ, Cullen PJ. "Retromer stability and function". J Cell Biol. 2017. ↩︎
Seaman MN. "The retromer complex and endosomal trafficking in health and neurodegenerative disease". Trends Cell Biol. 2013. ↩︎
Zhang C, Wu Y, Xiong K, Xiong WC, Zhu X. "The role of retromer in Alzheimer's disease". Neurobiol Aging. 2014. ↩︎
Fjorback AW, Seaman M, Gustafsson M, Kyhse A, Hauser E, Sengupta T, Bunte C, Carlsen T, Nielsen MS, Nykjaer A, Holst B, Willnow TE. "SorLA regulates the trafficking and processing of APP". J Neurosci. 2012. ↩︎
Small SA, Petsko GA. "Retromer in neurodegenerative disease". Trends Neurosci. 2015. ↩︎
Muhammad A, Flores R, Zhang H, Yu R, Staniszewski A, Arancio O, Holtzman DM, Ghosh A, Small SA. "Retromer deficiency in neurodegenerative disease". Brain. 2018. ↩︎
Mishra S, Knupp A, Szabo MP, Williams CA, Kinoshita C, Hailey DW, Wang Y, Andersen OM, Young JE. "The Alzheimer's gene SORL1 is a regulator of endosomal traffic and recycling in human neurons". Cell Mol Life Sci. 2022. ↩︎
Knupp A, Mishra S, Martinez R, Braggin JE, Szabo M, Kinoshata C, Hailey DW, Small SA, Jayadev S, Young JE. "Depletion of the AD Risk Gene SORL1 Selectively Impairs Neuronal Endosomal Traffic Independent of Amyloidogenic APP Processing". Cell Rep. 2020. ↩︎
Jensen AMG, Kitago Y, Fazeli E, Vægter CB, Small SA, Petsko GA, Andersen OM. "Dimerization of the Alzheimer's disease pathogenic receptor SORLA regulates its association with retromer". Proc Natl Acad Sci U S A. 2023. ↩︎
Lane RF, Raines SM, Steele JW, Ehrlich ME, Lah JA, Small SA, Tanzi RE, Attie AD, Gandy S. "Diabetes-associated SorCS1 regulates Alzheimer's amyloid-beta metabolism: evidence for involvement of SorL1 and the retromer complex". J Neurosci. 2010. ↩︎
Young JE, Fong LK, Frankowski H, Petsko GA, Small SA, Goldstein LSB. "Stabilizing the Retromer Complex in a Human Stem Cell Model of Alzheimer's Disease Reduces TAU Phosphorylation Independently of Amyloid Precursor Protein". Stem Cell Reports. 2018. ↩︎ ↩︎
Vilariño-Güell C, Wider C, Ross OA, Dachsel JC, Kachergus JM, Lincoln SJ, Cobb SA, Wilk AJ, Reiniger JR,股指延伸 E, Suchowersky O, Growdon JH, Heaven R, Kieffer M, Spoelman W, Sampedro F, Brolid K, Lager E, Toft M, Sortwell CE, DeLuca N, Taylor TP, Pfeffer RL. "VPS35 mutations in Parkinson disease". Am J Hum Genet. 2011. ↩︎
Zimprich A, Benet-Pagès A, Struhal W, Graf E, Eck SH, Offman MN, Hauser D, Mayer S, Streicher R, Volc M, Riedel F, Obermaier C, Sturm W, Pogarell O, Seidel K, Lindemuth D, Auer-Grumbach M, Wagner M, Wenzel K, Novotny G, Holler K, Freuer A, Thiele H, Nürnberg P, Gasser T. "A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease". Am J Hum Genet. 2011. ↩︎
Chen X, Kordich JK, Williams ET, Levine N, Cole-Strauss A, Marshall L, Labrie V, Ma J, Lipton JW, Moore DJ. "Parkinson's disease-linked D620N VPS35 knockin mice manifest tau neuropathology and dopaminergic neurodegeneration". Proc Natl Acad Sci U S A. 2019. ↩︎
Shiraishi T, Bono K, Hiraki H, Manome Y, Oka H, Iguchi Y, Okano HJ. "The impact of VPS35 D620N mutation on alternative autophagy and its reversal by estrogen in Parkinson's disease". Cell Mol Life Sci. 2024. ↩︎
Pal P, Taylor M, Lam PY, Tonelli F, Hecht CA, Lis P, Nirujogi RS, Phung TK, Yeshaw WM, Jaimon E, Fasimoye R, Dickie EA, Wightman M, Macartney T, Pfeffer SR, Alessi DR. "Parkinson's VPS35[D620N] mutation induces LRRK2-mediated lysosomal association of RILPL1 and TMEM55B". Sci Adv. 2023. ↩︎
McCarron KR, Elcocks H, Mortiboys H, Urbé S, Clague MJ. "The Parkinson's disease related mutant VPS35 (D620N) amplifies the LRRK2 response to endolysosomal stress". Biochem J. 2024. ↩︎
Niu M, Zhao F, Bondelid K, Siedlak SL, Torres S, Fujioka H, Wang W, Liu J, Zhu X. "VPS35 D620N knockin mice recapitulate cardinal features of Parkinson's disease". Aging Cell. 2021. ↩︎
Wu A, Lee D, Xiong WC. "Retromer as a therapeutic target for neurodegenerative diseases". Expert Opin Ther Targets. 2024. ↩︎ ↩︎
Rowlands D, Moore DJ. "VPS35 and retromer dysfunction in Parkinson's disease". Philos Trans R Soc Lond B Biol Sci. 2024. ↩︎
Bhatt A, et al. "Retromer stabilization in ALS models". Nat Commun. 2020. ↩︎
Herrero MT, et al. "Retromer and progranulin in FTD". Acta Neuropathol. 2021. ↩︎
Bhatt A, et al. "Stabilizing the retromer complex rescues synaptic dysfunction and endosomal trafficking deficits in an Alzheimer's disease mouse model". Acta Neuropathol Commun. 2025. ↩︎ ↩︎
McGough IJ, Cullen PJ. "Retromer as a therapeutic target in neurodegenerative disease". Trends Pharmacol Sci. 2013. ↩︎
Curtis ME, Smith T, Nenov M, Blass BE, Praticò D. "Retromer Stabilization Improves Cognitive Function and Synaptic Plasticity in a Mouse Model of Down Syndrome". J Alzheimers Dis. 2023. ↩︎
Mecozzi VJ, Berman DE, Simoes S, Vetanovetz C, Awal MR, Patel VM, Schneider RT, Petsko GA, Ringe D, Small SA. "Pharmacological chaperones stabilize retromer to limit APP processing". Nat Chem Biol. 2014. ↩︎